This is a preprint.
Network Analysis of Neuropsychiatric Symptoms in Alzheimer's Disease
- PMID: 37163090
- PMCID: PMC10168435
- DOI: 10.21203/rs.3.rs-2852697/v1
Network Analysis of Neuropsychiatric Symptoms in Alzheimer's Disease
Update in
-
Network analysis of neuropsychiatric symptoms in Alzheimer's disease.Alzheimers Res Ther. 2023 Aug 11;15(1):135. doi: 10.1186/s13195-023-01279-6. Alzheimers Res Ther. 2023. PMID: 37568209 Free PMC article.
Abstract
Background: Neuropsychiatric symptoms due to Alzheimer's disease (AD) and mild cognitive impairment (MCI) can decrease quality of life for patients and increase caregiver burden. Better characterization of neuropsychiatric symptoms and methods of analysis are needed to identify effective treatment targets. The current investigation leveraged the National Alzheimer's Coordinating Center (NACC) Uniform Data Set (UDS) to examine the network structure of neuropsychiatric symptoms among symptomatic older adults with cognitive impairment. Methods: The network relationships of behavioral symptoms was estimated from Neuropsychiatric Inventory Questionnaire (NPI-Q) data acquired from 12,494 older adults with MCI and AD during their initial visit. Network analysis provides insight into the relationships among sets of symptoms and allows calculation of the strengths of the relationships. Nodes represented individual NPI-Q symptoms and edges represented the pairwise dependency between symptoms. Node centrality was calculated to determine the relative importance of each symptom in the network. Results: The analysis showed patterns of connectivity among the symptoms of the NPI-Q. The network ( M =.28) consisted of mostly positive edges. The strongest edges connected nodes within symptom domain. Disinhibition and agitation/aggression were the most central symptoms in the network. Depression/dysphoria was the most frequently endorsed symptom, but it was not central in the network. Conclusions: Neuropsychiatric symptoms in MCI and AD are highly comorbid and mutually reinforcing. The presence of disinhibition and agitation/aggression yielded a higher probability of additional neuropsychiatric symptoms. Interventions targeting these symptoms may lead to greater neuropsychiatric symptom improvement overall. Future work will compare neuropsychiatric symptom networks across dementia etiologies, informant relationships, and ethnic/racial groups, and will explore the utility of network analysis as a means of interrogating treatment effects.
Conflict of interest statement
Competing Interests
JLC has provided consultation to Acadia, Actinogen, Acumen, AlphaCognition, Aprinoia, AriBio, Artery, Biogen, BioVie, Cassava, Cerecin, Diadem, EIP Pharma, Eisai, GemVax, Genentech, GAP Innovations, Janssen, Jocasta, Karuna, Lilly, Lundbeck, LSP, Merck, NervGen, Novo Nordisk, Oligomerix, Optoceutics, Ono, Otsuka, PRODEO, Prothena, ReMYND, Roche, Sage Therapeutics, Signant Health, Simcere, Suven, SynapseBio, TrueBinding, Vaxxinity, and Wren pharmaceutical, assessment, and investment companies.
Figures




Similar articles
-
Network analysis of neuropsychiatric symptoms in Alzheimer's disease.Alzheimers Res Ther. 2023 Aug 11;15(1):135. doi: 10.1186/s13195-023-01279-6. Alzheimers Res Ther. 2023. PMID: 37568209 Free PMC article.
-
Subscale validation of the neuropsychiatric inventory questionnaire: comparison of Alzheimer's disease neuroimaging initiative and national Alzheimer's coordinating center cohorts.Am J Geriatr Psychiatry. 2013 Jul;21(7):607-22. doi: 10.1016/j.jagp.2012.10.027. Epub 2013 Apr 18. Am J Geriatr Psychiatry. 2013. PMID: 23602309 Free PMC article.
-
Associations between dementia staging, neuropsychiatric behavioral symptoms, and divorce or separation in late life: A case control study.PLoS One. 2023 Aug 16;18(8):e0289311. doi: 10.1371/journal.pone.0289311. eCollection 2023. PLoS One. 2023. PMID: 37585365 Free PMC article.
-
Neuropsychiatric assessment of Alzheimer's disease and related dementias.Aging (Milano). 2001 Jun;13(3):240-6. doi: 10.1007/BF03351482. Aging (Milano). 2001. PMID: 11444257 Review.
-
Neuropsychiatric symptoms in Brazilians with mild cognitive impairment and dementia.Alzheimers Dement (Amst). 2021 Oct 14;13(1):e12219. doi: 10.1002/dad2.12219. eCollection 2021. Alzheimers Dement (Amst). 2021. PMID: 34692976 Free PMC article. Review.
References
-
- McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging‐ Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia. 2011. May;7(3):263–9. - PMC - PubMed
-
- Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging‐Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia. 2011. May;7(3):270–9. - PMC - PubMed
-
- Chung JA, Cummings JL. Neurobehavioral and neuropsychiatric symptoms in Alzheimer’s disease. Neurologic Clinics. 2000. Nov;18(4):829–46. - PubMed
Publication types
Grants and funding
- P20 AG068053/AG/NIA NIH HHS/United States
- P30 AG066515/AG/NIA NIH HHS/United States
- P30 AG062421/AG/NIA NIH HHS/United States
- P30 AG066519/AG/NIA NIH HHS/United States
- P30 AG072973/AG/NIA NIH HHS/United States
- P30 AG066462/AG/NIA NIH HHS/United States
- P30 AG066530/AG/NIA NIH HHS/United States
- P20 AG068077/AG/NIA NIH HHS/United States
- P30 AG066546/AG/NIA NIH HHS/United States
- P30 AG072972/AG/NIA NIH HHS/United States
- P30 AG072979/AG/NIA NIH HHS/United States
- P20 AG068082/AG/NIA NIH HHS/United States
- P30 AG072975/AG/NIA NIH HHS/United States
- P30 AG066444/AG/NIA NIH HHS/United States
- P30 AG066507/AG/NIA NIH HHS/United States
- P30 AG072946/AG/NIA NIH HHS/United States
- P30 AG066518/AG/NIA NIH HHS/United States
- R35 AG071476/AG/NIA NIH HHS/United States
- P30 AG066511/AG/NIA NIH HHS/United States
- U24 AG072122/AG/NIA NIH HHS/United States
- P30 AG066512/AG/NIA NIH HHS/United States
- U01 NS093334/NS/NINDS NIH HHS/United States
- P30 AG066508/AG/NIA NIH HHS/United States
- P30 AG072978/AG/NIA NIH HHS/United States
- P30 AG062429/AG/NIA NIH HHS/United States
- P30 AG062422/AG/NIA NIH HHS/United States
- R01 AG079280/AG/NIA NIH HHS/United States
- P20 GM109025/GM/NIGMS NIH HHS/United States
- P30 AG066509/AG/NIA NIH HHS/United States
- P30 AG072977/AG/NIA NIH HHS/United States
- R01 AG053798/AG/NIA NIH HHS/United States
- P30 AG062677/AG/NIA NIH HHS/United States
- P20 AG068024/AG/NIA NIH HHS/United States
- P30 AG072958/AG/NIA NIH HHS/United States
- P30 AG062715/AG/NIA NIH HHS/United States
- P30 AG066506/AG/NIA NIH HHS/United States
- P30 AG066468/AG/NIA NIH HHS/United States
- P30 AG072976/AG/NIA NIH HHS/United States
- P30 AG072947/AG/NIA NIH HHS/United States
- P30 AG072931/AG/NIA NIH HHS/United States
- P30 AG066514/AG/NIA NIH HHS/United States
- P30 AG072959/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources